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Objectives: Electroencephalography (EEG) may be a promising source of physiological bio-
markers accompanying chronic pain. Several studies in patients with chronic neuropathic pain 
have reported alterations in central pain processing, manifested as slowed EEG rhythmicity 
and increased EEG power in the brain’s resting state. We aimed to investigate novel potential 
markers of chronic pain in the resting state EEG of patients with chronic pancreatitis.
Participants: Resting state EEG data from 16 patients with persistent abdominal pain due to 
chronic pancreatitis (CP) were compared to data from healthy controls matched for age, sex 
and education.
Methods: The peak alpha frequency (PAF) and power amplitude in the alpha band (7.5–13 Hz) 
were compared between groups in four regions of interest (frontal, central, parietal, and occipital) 
and were correlated with pain duration.
Results: The average PAF was lowered in CP patients compared with that in healthy controls, 
observed as a statistically significant between-group effect (mean 9.9 versus 9.5 Hz; P=0.049). 
Exploratory post hoc analysis of average PAF per region of interest revealed a significant dif-
ference, particularly in the parietal and occipital regions. In addition, we observed a significant 
correlation between pain duration and PAF and showed increased shifts in PAF with longer pain 
durations. No significant group differences were found in peak power amplitudes.
Conclusion: CP pain is associated with alterations in spontaneous brain activity, observed as 
a shift toward lower PAF. This shift correlates with the duration of pain, which demonstrates 
that PAF has the potential to be a clinically feasible biomarker for chronic pain. These findings 
could be helpful for assisting diagnosis, establishing optimal treatment, and studying efficacy 
of new therapeutic agents in chronic pain patients.
Keywords: chronic pain, neuropathic pain, chronic pancreatitis, electroencephalography, 
EEG, alpha oscillations, peak frequency
Introduction
Diagnosis and treatment of chronic pain is challenging because by definition, pain is 
a subjective experience and can be measured only by self-report.1 Identification of 
physiological pain biomarkers for 1) disease severity, 2) disease progression, 3) disease 
prognosis, and 4) treatment effects, including indication and responder identification, 
could help us to improve pain diagnostics and treatment. Increasing evidence supports 
the idea that chronic pain can be understood not only as an altered perceptual state, but 
also as a consequence of alterations in peripheral and central neuronal processing.
Electroencephalography (EEG) can be a useful method to detect such alterations 
in central pain processing.2–4 The resting state EEG with eyes closed is dominated by 
oscillations in the alpha band (7.5–13 Hz), which are widely distributed in the cerebral 
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cortex and more prominent in the parietal and occipital 
regions. Resting EEG is commonly analyzed by transform-
ing data from the time domain to the frequency domain. The 
peak alpha frequency (PAF) is a measure derived from that 
analysis, and is defined by two parameters: 1) the frequency 
at which it occurs on the frequency axis; and 2) its amplitude 
on the power–density axis.
Sarnthein et al2 observed increased power amplitude dif-
ferences in the alpha band, and a shift toward lower frequen-
cies of the dominant peak in patients with mixed neurogenic 
pain syndromes. These results are supported by other resting 
state EEG studies investigating alterations in central pain 
processing in various chronic pain states.3,5–7 Similar altera-
tions in EEG activity were reported in patients with chronic 
pancreatitis, observed as an increase in power amplitude in 
the theta and alpha frequency bands.4,8 However, PAF and 
its relation to clinical pain parameters were not investigated 
in these studies.
Chronic pancreatitis (CP) is a disease characterized by 
inflammation and progressive destruction of the pancreatic 
gland, which results in irreversible morphologic changes 
that typically cause pain and/or exocrine and endocrine 
insufficiency.9 The most important symptom of CP is abdomi-
nal pain, present in 80%–90% of patients during the time 
course of the disease.10 Pancreatic pain is typically intense, 
long-lasting, and difficult to treat. Alterations in pancreatic 
nerves, including an increase in number and diameter of 
nerve fibers and an increased number of neurotransmitters,11,12 
as well as alterations in central pain processing, including 
supraspinal sensitization, somatotopic reorganization, and 
pro-nociceptive pain modulation, have been proposed as pos-
sible mechanisms underlying chronic pain in CP.13–15 Altered 
central pain processing was demonstrated in a previous study 
in CP patients using quantitative sensory testing, manifested as 
a widespread hyperalgesia, ie, an increased pain sensitivity,16 
in distant, nondamaged tissues. This can be interpreted as a 
sign of spinal, supraspinal (cortical), or combined sensitiza-
tion.17 These observations support the role of central neuronal 
plasticity in the pain accompanying CP. If that is correct, 
therapies exclusively directed at the pancreas as the nocicep-
tive source are unlikely to be effective in achieving pain relief. 
Therefore, patients who might benefit from a treatment target-
ing central pain mechanisms need to be identified.
In the current study, we aim to investigate the brain’s 
resting state activity within the alpha frequency band in 
patients with chronic pain resulting from CP: 1) to research 
novel potential EEG biomarkers; 2) to investigate biomarker 
scalp localization; 3) to study effects of disease progression 
on biomarkers; and 4) to address the clinical usefulness of 
EEG biomarkers for CP pain.
Methods
subjects
Sixteen patients with persistent abdominal pain resulting 
from CP were selected at random from those with CP seen 
at the outpatient clinic of the Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands. CP was diag-
nosed based on medical history, laboratory tests, and radio-
logical findings according to the Marseille and Cambridge 
Classification System.18 All patients had typical pancreatic 
pain, which is characterized as severe, dull epigastric pain, 
eventually radiating to the back. Intake of analgesics includ-
ing opioids and centrally acting medication was permitted. 
Patients with present alcohol use were excluded. The healthy 
controls (HC) group comprised 16 healthy participants 
matched by age, sex, and years of education to the CP group. 
Previous studies suggest that this is an appropriate sample 
size to investigate the resting state EEG.2,6,19
Medical-ethical approval was obtained for the measure-
ments in HCs (Committee on Research involving Human 
Subjects, Region Arnhem-Nijmegen Number 2002/008). 
All patients were referred by their physician in charge for 
neuropsychological/neurophysiological testing as part of their 
medical follow-up. The neurophysiologic testing results have 
already been published and revealed a decline in cognitive 
performance in the CP group.20 Both patients and healthy 
participants gave written informed consent to use the data 
for scientific purposes.
eeg recording
EEG data were collected according to a standardized proto-
col using a Quickcap (NuAmps, Compumedics Neuroscan, 
Singen, Germany) with 26 scalp electrodes located according 
to the International 10–20 system (Fp1, Fp2, F7, F3, Fz, F4, 
F8, FC3, FCz, FC4, T3, C3, Cz, C4, T4, CP3, CPz, CP4, 
T5, P3, Pz, P4, T6, O1, Oz, O2).21 Electrooculogram data 
were recorded from electrodes above and below the left eye 
and lateral to the outer canthi of each eye. Additional physi-
ological data were obtained from the orbicularis oculus and 
the masseter muscles. Data were recorded at a sampling rate 
of 500 Hz and offline referenced to the mean of the signals 
recorded at the mastoids. The ground electrode was placed 
at the Fpz location. Electrode impedance was kept below 5 
kΩ for all electrodes.
The spontaneous EEG or resting EEG was recorded during 
eyes closed and eyes open. Each recording lasted 2 minutes. 
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All results presented in this study refer to the eyes-closed 
condition to avoid artifacts; alpha activity is typically present 
during this condition. During the recording in eyes-closed 
position, participants were seated in a comfortable chair 
and were asked to close their eyes and relax. No further task 
was given.
eeg analysis
Brain Vision Analyzer 2.0 software (Brain Products GmbH, 
Gilching, Germany) was used for EEG analysis. EEG 
data were band-pass filtered (1–120 Hz; phase shift-free 
Butterworth filters), and corrected for ocular artifacts 
according to the Gratton and Coles algorithm.22 Each EEG 
recording was segmented into 12 epochs of 10 seconds 
each. Subsequently, epochs were inspected for artifacts and 
rejected for further analysis if data exceeded an amplitude 
of 200 µV or exceeded the maximal allowed voltage step of 
50 µV. This resulted in 1.7% rejection of all epochs, mainly 
those concerning temporal electrodes. The power amplitudes 
of the EEG frequencies were computed using a fast Fourier 
transformation. To this end, epochs were multiplied by a 
Hanning window (10%) and Fourier-transformed; spectral 
distributions were averaged across all epochs for each par-
ticipant and electrode separately.
Data analysis and statistics
Grand average power spectra were computed by averaging all 
scalp electrodes for each participant. These grand averages 
were averaged per group to obtain the overall power. Peak 
power amplitudes were determined as the maximum value 
between 7.5–13 Hz within empirically defined regions of 
interest (ROIs). Positively skewed peak power amplitudes 
were log-transformed to normalize the data. A lack of 
lateralization, as shown in topographical distribution plots, 
provides the opportunity to average individual electrodes 
in the ROIs to obtain a more stable, but targeted, analysis. 
Hence, four horizontally arranged ROIs were designated: the 
frontal (Fp1, Fp2, F3, Fz, F4), central (FC3, FCz, FC4, C3, 
Cz, C4), parietal (CP3, CPz, CP4, P3, Pz, P4), and occipital 
(O1, Oz, O2) ROIs.
Different methods can be used to quantify the variation 
of spectral distribution within the alpha range.23 First, 
PAF can be measured by calculating the frequency with 
the highest magnitude within the alpha range. Second, the 
center of gravity, rather than peak, can be measured. This 
gravity method has been used as a different, and possibly 
more stable, measure of spectral distribution than the peak 
method.23,24 In particular, if there are multiple peaks in the 
alpha range, the gravity method appears the more adequate 
estimate of the PAF.23 In the current study, a few participants 
demonstrated low-voltage EEG without clear peaks within 
the alpha band. The center of gravity method was assumed 
to be most appropriate, because this method enables analysis 
of the entire dataset without excluding low-voltage EEG 
subjects from analysis. All participants demonstrated at least 
some peak within the 7.5–13 Hz range, assumed as the alpha 
frequency band and were included for further analyses. The 
PAF is the weighted sum of spectral estimates, divided by 
alpha power, as calculated by the following equation:25







 =Amplitude of frequency f
f =Frequencies within 7.5–13 Hz range (per 0.1 Hz).
For statistical analysis, we used SPSS software for 
Windows version 16.0 (IBM Corporation, Armonk, NY, USA). 
All variables were visually inspected and the Kolmogorov–
Smirnoff Test was applied to test data distributions. A t-test 
for independent samples was applied on normally distributed 
data; otherwise a non-parametric Mann–Whitney U test was 
used. A General Linear Model (GLM; StatSoft, Tulsa, OK, 
USA) repeated measures analysis of variance (RM-ANOVA) 
was used to test whether there were statistically significant 
differences regarding PAF and peak power amplitudes 
between CP patients and HCs with respect to the ROI (frontal, 
central, parietal and occipital). Our dependent variable, the 
PAF, was normally distributed, allowing parametric testing. 
Mauchly’s test indicated that the assumption of sphericity had 
been violated. Therefore, degrees of freedom were corrected 
using Greenhouse–Geisser estimation. Post hoc analyses 
included exploratory pair-wise testing of each region of 
interest separately, using two-sided unpaired t-tests. A GLM 
repeated-measures ANOVA was used to test whether there 
were significant differences between opioid and nonopioid 
users and between the different etiologies of CP, with respect 
to the ROI. In addition, pain duration was correlated with 
EEG parameters using the nonparametric Spearman test. 
Controls did not have pain and were allocated zero scores on 
pain duration, and were included in this analysis. In all tests, 
the significance level was set at P,0.05.
Results
Research population
The CP patients had a mean pain duration of 5.4 years; eight 
patients had a history of alcohol abuse and nine patients used 
opioid medication for pain relief (Table 1). Matched controls 
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did not use centrally acting medication and all were pain free, 
expressed as zero scores on pain duration. No differences 
were observed between the CP and HC group with respect 
to age, sex, and years of education (Table 2).
grand average power spectra
Absolute values of grand average power spectra amplitudes 
within the alpha band are summarized for CP patients and 
HC in Figure 1. No significant group differences were found 
in the logarithmically transformed peak power amplitudes. 
The corresponding PAF was significantly shifted toward 
lower EEG frequencies in the CP group compared with 
the HC group (mean ± SD: 9.9 ± 0.4 versus 9.5 ± 0.5 Hz; 
95% confidence interval [CI] of mean difference =−0.68 
to −0.01 Hz; P,0.05). Moreover, pain duration was sig-
nificantly correlated with the grand average PAF (r=−0.379; 
P=0.032), showing increased reductions in PAF with longer 
pain durations (Figure 2).
Topographical power distributions
Differences in grand average power spectra between both 
groups were restricted to the frequency range between 
7.5 and 10 Hz (Figure 1). Thus, we restricted the topo-
graphical analysis of EEG power to this part of the alpha 
band (Figure 3A–F). The topographical distribution plots 
showed maximum EEG alpha power in both groups, as well 
as maximum group differences, to be situated in the parietal 
and occipital regions.
Power spectra
The average power frequency distributions were plotted 
separately per ROI in Figure 4A–D. This Figure suggests 
increased peak power amplitudes in CP patients compared 
with the HC group in each of the ROIs, particularly parietal 
and occipital. However, logarithmically transformed peak 
power amplitudes did not differ significantly in any of the 
ROIs (Table 3).
Peak alpha frequency
The mean PAF for each of the ROIs is shown in Figure 5. 
A statistically significant between-group effect was observed 
regarding the PAF in CP patients compared with HC (F =4.20; 
P=0.049). Within-group testing revealed a statistically sig-
nificant difference among the ROIs (F =11.62; P,0.001). No 
significant interaction was observed between the effects of 
group and ROIs on the PAF (F =2.785; P=0.085). Exploratory 
post hoc testing resulted in significant differences between 
Table 1 Demographic and clinical characteristics of individual patients with chronic pancreatitis
No Age 
(years)
Sex Etiology Pain 
(years)
Opioids Other drugs
1 28 F hereditary 6 Ms-contin® PPi
2 50 M idiopathic 5 – PPi
3 57 F alcohol abuse 10 Durogesic –
4 40 M alcohol abuse 6 Morphine PM; nsaiD
5 51 M alcohol abuse 6 Temgesic –
6 54 M alcohol abuse 8 Morphine aD
7 58 M alcohol abuse 4 Tramadol PM; ae
8 39 F idiopathic 10 Durogesic/pethidine –
9 46 F idiopathic 2 Oxycontin –
10 72 M idiopathic 6 – PPi; nsaiD
11 50 M alcohol abuse 10 – PM
12 48 M Biliary 4 Oxycontin ae; BZ; PM
13 56 M alcohol abuse 2 – PM; PPi
14 24 F idiopathic 2 – –
15 52 F alcohol abuse 5 – ae; BZ; PM; li
16 59 M idiopathic 1 – PPi
Mean (sD) 5,4 (2,9)
Notes: Relevant drugs include antiepileptics (AE), benzodiazepines (BZ), antidepressants (AD), lithium (Li), non-steroidal anti-inflammatory drug (NSAID), paracetamol 
(PM) and proton pump inhibitors (PPi).
Abbreviations: F, female; M, male; sD, standard deviation; Ms, morphine sulfate.
Table 2 Demographic and clinical characteristics of healthy 
controls and chronic pancreatitis patients
HC CP P-value
n 16 16
Male/female 10/6 10/6 ns
Mean (sD)  
age (years)
48.0 (11.27) 49.5 (11.91) ns
Mean (sD)  
education (years)
11.9 (2.86) 11.8 (3.09) ns
Abbreviations: hc, healthy controls; cP, chronic pancreatitis patients; ns, not 
significant; N, number; SD, standard deviation.
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patients and controls regarding the PAF in the parietal and 
occipital ROIs (Table 3).
The mean PAF in CP patients using opioid medication 


















Figure 1 grand average frequency power distributions averaged across all channels in patients with chronic pancreatitis (cP) compared to healthy controls (hc).
Notes: This figure shows a shift toward lower frequencies and an increased amplitude in CP patients compared with HC.
9.5 ± 0.5 Hz, respectively. Opioid use as between-group fac-
tor in the RM-ANOVA indicated no significant differences 
regarding PAF (F=0.015; P=0.904) or peak power amplitudes 
(F=1.593; P=0.228). Opioid use as covariate did not modify 
the main between-group effect. Subgroups of patients with 
or without alcohol abuse in history did not show significant 
differences regarding PAF (F=0.063; P=0.806) or peak power 
amplitudes (F=1.984; P=0.181).
Discussion
We observed a significant shift toward lower frequencies in 
patients with CP compared with healthy controls, recorded as 
a decrease in PAF over all scalp electrodes. These results are 
consistent with other studies investigating the brain’s default 
state in chronic pain patients, including patients with CP, 
reported as a slowing of EEG oscillations.2–5,7 Exploratory 
post hoc analysis of average PAF per ROI reveals a significant 
difference, particularly in parietal and occipital regions. 
Furthermore, the present study shows that longer pain dura-
tions are associated with greater declines in PAF, indicating 
that PAF might be a marker for disease progression.
Table 3 Peak alpha frequency (PaF) and logarithmized peak 





PaF 9.7 (0.50) 9.4 (0.46) 0.190
logarithmized peak power −0.39 (0.98) −0.19 (1.09) 0.586
Central ROI
PaF 9.8 (0.42) 9.5 (0.49) 0.091
logarithmized peak power −0.31 (1.08) −0.04 (0.97) 0.462
Parietal ROI
PaF 9.9 (0.41) 9.6 (0.50) 0.037*
logarithmized peak power 0.21 (0.97) 0.31 (1.34) 0.811
Occipital ROI
PaF 10.0 (0.47) 9.6 (0.59) 0.019*
logarithmized peak power −0.24 (1.59) 0.32 (1.59) 0.332
Note: *P,0.05.
Abbreviations: ROi, regions of interest; sD, standard deviation.
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alpha oscillations in the resting state eeg
Continuous EEG is dominated by alpha band oscillations 
(7.5–13 Hz), which are widely distributed in the cerebral cortex 
and recorded with larger amplitudes over posterior regions with 
the eyes closed.25 The exact role of alpha oscillations remains 
unclear, but several factors have been identified affecting the 
alpha activity in some way. The PAF, a primary measure 
of alpha activity, starts to decline with increasing age26 and 
is known to increase with cognitive processing, attentional 
demand, and arousal.27 Several studies have found PAF to be a 
stable measure, showing a high intra-individual stability.28, 29
spontaneous alpha oscillations  
in chronic pain
Multiple studies report that phasic, as well as tonic, painful 
stimuli suppress spontaneous oscillations over the cortex 
in healthy participants,19,30 but only a few studies have 
investigated the brain default state in patients with chronic 
pain. Sarnthein et al2 reported an increased EEG power and 
a slowed dominant peak frequency in patients with severe 
neuropathic pain of various origins. Maximal differences 
appeared in the 7–9 Hz band in all electrodes. These results 
were explained by the concept of thalamocortical dysrhyth-
mia (TCD), which is proposed as a general mechanism to 
explain the generation of neuropathic pain and other neuro-
logical symptoms.2,3,31 TCD is based on diminished excitatory 
or increased inhibitory input of neurons in the thalamus, 
resulting in the presence of a persistent low-frequency, 
thalamocortical resonance during the awake state.3 This 
mechanism has been supported by the finding that therapeutic 
surgical lesions in the thalamus resulted in normalization of 
EEG activity as well as providing pain relief.2
Two studies in patients with neuropathic pain following 
spinal cord injury (SCI) support the TCD theory. In both stud-
ies, peak frequency was shifted towards lower frequencies 
in SCI patients with pain as compared with SCI patients 
without pain. In contrast, no differences were observed in 
















Figure 2 individual pain durations and grand average peak alpha frequencies of both chronic pancreatitis patients and healthy controls (hc).
Notes: hc were all pain free, expressed as zero scores on pain duration. A significant correlation was found (r =−0.379; P=0.032), indicating that an increase in pain duration 
is correlated with an increased shift of PaF.
Abbreviation: PaF, peak alpha frequency.
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patients with chronic low back pain, who did not demon-
strate any statistically significant TCD effect, according to 
a study by Schmidt et al.32 Only in a subsample of patients 
showing evidence of root damage was a trend for significant 
effect observed. The authors of that study suggest that only 
patients with severe pain or neuropathic pain develop the 
typical TCD pattern. This may be, as stated earlier, because 
pancreatic pain is typically intense and long lasting, and also 
because pancreatic pain may be of neuropathic origin.8,33
A previous study in CP patients with pain showed slow-
ing of EEG rhythms based on increased normalized power 
amplitudes in the lower frequency bands, including the 
alpha band.4 The present study confirms those results in a 
similar population of CP patients. It extends those results to 
additional EEG parameters, better quantifying alpha-slowing 
using PAF, and establishes a relation to clinically relevant 
factors such as pain duration. Interestingly, based on our PAF, 
maximum differences between groups were located over the 
posterior regions, whereas Olesen et al4 reported that mainly 
the frontal electrodes contributed to the  difference based 
on normalized amplitude strengths. However, both studies 
observed slowing of EEG rhythmicity, which suggests that 
pancreatic pain originates from a disturbance in thalamo-
cortical rhythmia.
Toward a biomarker for chronic pain
A simple self-evaluation of pain is not sufficient to provide 
insight into underlying mechanisms because multiple factors 
potentially affect the pain experience. Therefore, develop-
ment of a physiological measure reflecting underlying pain 
mechanisms is desirable. First, it may improve pain diag-
nostics through addition of a mechanism-oriented parameter 
that reflects central neuronal involvement in pain genesis 
and maintenance. Second, it may improve pain treatment by 
identification of patients who may benefit from a treatment 
targeting central pain mechanisms. Graversen et al34 have 
shown that quantitative pharmaco-EEG can be used to moni-
tor the central analgesic mechanisms of pregabalin, and they 
suggest that this approach may be used to predict effect of 
treatment leading to pharmaco-diagnostic testing.
HC
CP
∆ (HC – CP)
 A; 7.5–8.0 Hz B; 8.0–8.5 Hz C; 8.5–9.0 Hz  D; 9.0–9.5 Hz  E; 9.5–10.0 Hz  F; 10.0–10.5 Hz
−1.20 µV 1.20 µV0
A B C D E F
Figure 3 average topographical power distributions of the resting electroencephalogram.
Notes: The average topographical distributions of electroencephalography power showed the maximum amplitudes in the parietal-occipital regions in both chronic 
pancreatitis (cP) patients and healthy controls (hc). scalp distributions are shown for frequency spectra within the alpha band.
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clinical applications of eeg
Beside the fact that EEG measures different phenomena 
regarding brain function than functional MRI (fMRI) or 
positron emission tomography (PET), EEG has several 
advantages: 1) PET and fMRI are based on the  measurement 
of secondary metabolic changes in brain tissue, but not 
of primary electrical effects of neural excitation; 2) EEG 
equipment costs significantly less than neuro-imaging 
equipment; and 3) EEG equipment, including electrodes, 
a signal amplifier, and a computer with EEG software, is 
portable and easy to apply. This enables us to record the 
EEG near the patient’s bed. Conversely, it usually takes 
a long time to apply numerous electrodes at the scalp; 
therefore, it would be desirable to reduce the number of 
required electrodes in clinical practice. But which elec-
trodes are superfluous? Our study showed the maximum 
alpha-band oscillations in both groups to be located in the 
parietal and occipital regions. More importantly, differences 
between groups in PAF, the only discriminative parameter 
observed in our study, were located over the same posterior 
regions. This suggests that PAF is best measured in the 
parietal and occipital regions of the scalp for chronic pain 
diagnostics.
Methodological considerations
Future research should concentrate on limitations within the 
current study. First, we did not collect pain scores during or 
just preceding the measurement or average pain scores over 
the past few months. Therefore, it was not possible for us to 
correlate pain intensities with EEG parameters. Second, we 
made a comparison of CP patients with pain versus healthy 






































































Figure 4 averaged power distributions within the frontal (A), central (B), 
parietal (C), and occipital (D) regions of interest in chronic pancreatitis patients 
compared to healthy controls.

















Figure 5 Peak alpha frequency in four regions of interest shown for patients with 
chronic pancreatitis compared with healthy controls.
Notes: Red squares correspond to mean PaF in patients, green triangles 
correspond to mean PaF in controls, and short lines represent corresponding 
standard deviations. Asteriks indicate significant differences.
Abbreviations: ROi, region of interest; PaF, peak alpha frequency.
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We recruited a homogeneous group of patients, all suffering 
from persistent visceral pain resulting from diagnosed CP. 
Although these patients were homogeneous with respect to 
the cause of pain, it is difficult to ascribe the observed changes 
in the resting EEG to just one underlying cause. Variations in 
pain duration, as well as differences in etiology (eg, history 
of alcoholism), comorbidity (eg, exocrine and/or endocrine 
failure), surgical treatment history, and actual medication 
use may be contributing factors. Thus, it might be interest-
ing to investigate the influence of these factors based on a 
third group of CP patients without pain. However, it will be 
challenging to find CP patients having no pain and matched 
by age, level of education, and medication intake, which are 
evident factors effecting the resting EEG.
Centrally acting medication might influence the brain’s 
resting-state activity. Many patients with CP use analge-
sics, including opioids, for pain treatment. This presents 
an ethical dilemma, as patients could potentially face 
severe pain if their medication were discontinued. In our 
study, more than half of the patients used opioids at the 
time of measurements. A comparison between subgroups 
of patients with and without opioids did not reveal any 
significant difference. Hence, the slowed PAF observed 
in our study is unlikely to have been caused by centrally 
acting medication.
Conclusion
The present study shows a shift of the alpha peak towards 
lower frequencies in CP patients with chronic pain com-
pared with healthy controls. This shift correlates with the 
duration of pain, which demonstrates that PAF deserves 
further study regarding its potential as a clinically useful 
biomarker for chronic pain. The subdivision in four ROIs 
showed that this biomarker is best measured in the parieto-
occipital regions of the scalp, which reduces the number of 
electrodes necessary; this is of benefit for clinical practice. 
Accordingly, this method appears promising in supporting 
diagnosis and prognosis, establishing optimal treatment, 
and studying efficacy of new therapeutic agents in chronic 
pain patients.
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